Perfil de la empresa · Healthcare

Qiagen NV

QGEN · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
28 de junio de 1996
Empleados
5500
Precio actual
$42.04
En vivo · 15 de julio de 2026
Compra razonable
≤ $32
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
42/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $42.04 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $30–$32 / razonable $39–$53 / optimista $58–$64. A $42.04, Dentro del rango de valor intrínseco razonable.

Al publicar $41.51 (17 de julio de 2026)

Capitalización7462,13 M US$
Ingresos (TTM)2098,86 M US$
EBITDA727,68 M US$
Margen neto19,16 %
ROE11,93 %
PER (TTM)18,46
PER previsto11,38
PEG0,91
BPA1,96 US$
Rentabilidad por dividendo0 %
Rango de 52 semanas32,53 US$ – 57,82 US$
Precio objetivo de analistas43,82 US$
Recomendación de analistas3.9 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.

Aún no hay análisis sobre este valor en tu idioma.